Clinical Trial Update: Ruxolitinib for Steroid-refractory GVHD [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ruxolitinib for steroid-refractory graft-versus-host disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: St. Petersburg State Pavlov Medical University | Conditions: Graft Vs Host Disease | Phase 2 | Status: COMPLETED